DOCUMENT
27/03/2024 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 27 March 2024 Page 1 of 11 East Region Formulary Committee Minutes Date: 27 March 2024 Time: 2.00pm – 4.00pm Location: MS Teams Present: Carla Capaldi ...
We have found 13 results when searching "Tocilizumab"
East Region Formulary ERFC Minutes 27 March 2024 Page 1 of 11 East Region Formulary Committee Minutes Date: 27 March 2024 Time: 2.00pm – 4.00pm Location: MS Teams Present: Carla Capaldi ...
East Region Formulary ERFC Minutes 02 October 2024 Page 1 of 12 East Region Formulary Committee Minutes Date: 02 October 2024 Time: 2.00pm – 3:15pm Location: MS Teams Present: Carla Capaldi ...
East Region Formulary ERFC Minutes 21 January 2026 Page 1 of 9 East Region Formulary Committee Minutes Date: 21 January 2026 Time: 2.00pm – 3:50pm Location: MS Teams Present: Alison Casey Seni...
East Region Formulary ERFC Minutes 7 June 2023 Page 1 of 17 East Region Formulary Committee Minutes Date: 7 June 2023 Time: 2pm – 4pm Location: MS Teams Present: Jane Browning (Acting) Assoc...
TA375 (SMC 593/09) : Moderate to severe active rheumatoid arthritis
754/12 : For the treatment of systemic Juvenile Idiopathic Arthritis
TA375 (SMC 774/12) : For the treatment of monotherapy in rheumatoid arthritis (RA) when biologic combination with methotrexate (MTX) is inappropriate [e.g. due to intolerance to MTX].
TA373 (SMC 930/13) : Tocilizumab in combination with methotrexate is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthriti...
982/14 : In combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intole...
1020/14 : Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.